vadimezan has been researched along with Neoplasms in 51 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (1.96) | 18.2507 |
| 2000's | 25 (49.02) | 29.6817 |
| 2010's | 20 (39.22) | 24.3611 |
| 2020's | 5 (9.80) | 2.80 |
| Authors | Studies |
|---|---|
| Ascano, M; Barchet, W; Dai, P; Deng, L; Gao, P; Hartmann, G; Patel, DJ; Tuschl, T; Wang, W; Zillinger, T | 1 |
| Xu, XL; You, QD; Zhang, H | 1 |
| Ahuja, V; Akhtar, F; Blum, J; Chaudhry, C; Cherney, EC; Chong, C; Fereshteh, M; Fink, B; Futran, A; Gangwar, S; Harner, M; Huynh, T; Li, S; Li-Wang, B; Lin, Z; Lo, J; Locke, GA; Monereau, L; Pan, C; Posy, SL; Quesnelle, C; Ruzanov, M; Sack, JS; Schieven, GL; Schroeder, GM; Vite, G; Wei, D; Zhang, L; Zhang, P; Zhu, X | 1 |
| Bai, H; Gao, Y; Geng, M; Li, Z; Niu, J; Wang, X; Xie, Z; Xu, Y; Yang, Y; Zhang, Y; Zhou, B | 1 |
| Ding, C; Geng, M; Li, X; Liu, Z; Ma, J; Shen, A; Song, Z; Wang, X; Xiao, R; Xie, Z; Zhang, A; Zhang, Y | 1 |
| Cen, S; Cui, X; Zhang, R; Zhou, J | 1 |
| Bryan Bell, R; Chen, G; Chen, Z; Ci, T; Dotti, G; Gu, Z; Li, H; Li, R; Meng, H; Wang, J; Wang, Z; Wen, D | 1 |
| Daei Farshchi Adli, A; Jahanban-Esfahlan, R; Samandari-Rad, S; Seidi, K; Zarghami, N | 1 |
| Chai, Z; Qian, R; Xiong, S; Xu, M; Yang, K; Yi, X; Zhao, L; Zhou, H | 1 |
| Fernandes, C; Pinto, MMM; Ribeiro, J; Tiritan, ME; Veloso, C | 1 |
| Bhat, N; Burdette, DL; Conlon, J; Fitzgerald, KA; Jiang, Z; Jin, T; Monks, B; Rathinam, VA; Sharma, S; Thompson, M; Vance, RE; Vogel, SN; Xiao, TS | 1 |
| Arina, A; Beckett, M; Burnette, B; Chen, ZJ; Darga, T; Deng, L; Fu, YX; Gajewski, TF; Huang, X; Li, XD; Liang, H; Mauceri, H; Weichselbaum, RR; Xu, M; Yang, X | 1 |
| Gevertz, JL | 1 |
| Rehman, F; Rustin, G | 1 |
| Acton, G; Baguley, BC; Green, C; Hogg, CR; Jameson, MB; Jeffery, M; McKeage, MJ; Sharp, DM; Sissingh, JI; Thompson, PI; Waller, S | 1 |
| Head, M; Jameson, MB | 2 |
| Baguley, BC; McKeage, MJ | 2 |
| Baguley, BC; Siemann, DW | 1 |
| Cai, YC; Xian, LJ; Zou, Y | 1 |
| Boerner, SA; Hunsberger, S; Lorusso, PM | 1 |
| Lenihan, DJ; Subbiah, IM; Tsimberidou, AM | 1 |
| Daga, H; Hida, T; Horio, Y; Ishikawa, S; Kobayashi, K; Shimizu, J; Takeda, K; Tokunaga, S | 1 |
| de Witte, P; Lerut, E; Marysael, T; Ni, Y | 1 |
| Du, Y; Flarakos, J; Fong, PC; Hong, X; Mangold, J; McKeage, MJ; Schran, H; Tanaka, C | 1 |
| Baguley, BC; Kestell, P; Paxton, JW; Zhou, S | 1 |
| Galbraith, SM; Gumbrell, L; Hough, D; Jameson, M; Lodge, MA; Padhani, AR; Rustin, GJ; Stirling, JJ; Taylor, NJ; Thompson, P | 1 |
| Baguley, BC; Wilson, WR | 1 |
| Horsman, MR; Murata, R | 1 |
| Baguley, BC | 2 |
| Berg, RW; Ching, LM; Kanwar, JR; Kanwar, RK; Krissansen, GW; Sun, X; Yang, Y | 1 |
| Baguley, BC; Bellenger, K; Evans, BD; Gumbrell, L; Halbert, GW; Harvey, VJ; Jameson, MB; Kestell, P; McCrystal, MR; Porter, DJ; Small, M; Thompson, PI | 1 |
| Thorpe, PE | 1 |
| Minton, NP | 1 |
| Bukowski, RM; Cooney, MM; Ortiz, J; Remick, SC | 1 |
| Baguley, BC; Kanthou, C; Tozer, GM | 1 |
| Baguley, BC; Fong, P; Jameson, MB; Jeffery, M; Kestell, P; McKeage, MJ; Ravic, M | 1 |
| Chaplin, DJ; Horsman, MR; Siemann, DW | 1 |
| Lorusso, PM; Pilat, MJ | 1 |
| Eskens, FA; Hinnen, P | 1 |
| Griffiths, JR; McPhail, LD; Robinson, SP | 1 |
| Baguley, BC; Baker, SD; Jameson, MB; Li, J; Pili, R | 1 |
| Pruijn, FB; Wilson, WR | 1 |
| Horsman, MR; Murata, R; Overgaard, J | 1 |
| Kestell, P; Paxton, JW; Tingle, MD; Zhou, S | 1 |
| Baguley, BC; Folkes, LK; Jameson, MB; Kestell, P; Stratford, MR; Zhao, L | 1 |
| Kestell, P; Paxton, JW; Tingle, MD; Zhou, SF | 1 |
| Bentzen, S; Galbraith, SM; Lodge, MA; Padhani, AR; Rustin, GJ; Stirling, JJ; Taylor, NJ | 1 |
20 review(s) available for vadimezan and Neoplasms
| Article | Year |
|---|---|
Targeting Stimulator of Interferon Genes (STING): A Medicinal Chemistry Perspective.
Topics: Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Autoimmune Diseases; Binding Sites; Chemistry, Pharmaceutical; Drug Delivery Systems; Humans; Membrane Proteins; Neoplasms; Protein Structure, Secondary; Signal Transduction | 2020 |
STING modulators: Predictive significance in drug discovery.
Topics: Autoimmune Diseases; Communicable Diseases; Drug Discovery; Humans; Membrane Proteins; Neoplasms; Nucleotides; Signal Transduction; Small Molecule Libraries; Xanthones | 2019 |
An overview on Vadimezan (DMXAA): The vascular disrupting agent.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Cytokines; Humans; Immunity, Innate; Neoplasms; NF-kappa B; Nitric Oxide; p38 Mitogen-Activated Protein Kinases; Xanthones | 2018 |
Carboxyxanthones: Bioactive Agents and Molecular Scaffold for Synthesis of Analogues and Derivatives.
Topics: Antineoplastic Agents; Drug Design; Humans; Neoplasms; Pyrones; Structure-Activity Relationship; Xanthones | 2019 |
ASA404: update on drug development.
Topics: Angiogenesis Inhibitors; Animals; Clinical Trials as Topic; Drug Design; Humans; Neoplasms; Neovascularization, Pathologic; Xanthones | 2008 |
Disrupting established tumor blood vessels: an emerging therapeutic strategy for cancer.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Clinical Trials as Topic; Combined Modality Therapy; Drug Screening Assays, Antitumor; Flavonoids; Humans; Neoplasms; Xanthones | 2010 |
Temporal aspects of the action of ASA404 (vadimezan; DMXAA).
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Clinical Trials as Topic; Endothelium, Vascular; Humans; Neoplasms; Xanthones | 2010 |
ASA404: a tumor vascular-disrupting agent with broad potential for cancer therapy.
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Endothelial Cells; Humans; Neoplasms; Neovascularization, Pathologic; Xanthones | 2010 |
[Advances in the study of the anti-tumor activity of small molecule vascular disrupting agents].
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Bibenzyls; Diphosphates; Endothelial Cells; Humans; Molecular Structure; Neoplasms; Neovascularization, Pathologic; Oligopeptides; Organophosphorus Compounds; Serine; Stilbenes; Tubulin Modulators; Xanthones | 2010 |
Pharmacokinetic evaluation of vadimezan (ASA404, 5,6-dimethylxanthenone-4-acetic acid, DMXAA).
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Drug Evaluation; Humans; Neoplasms; Randomized Controlled Trials as Topic; Xanthones | 2011 |
5,6-dimethylxanthenone-4-acetic acid (DMXAA): a new biological response modifier for cancer therapy.
Topics: Animals; Antineoplastic Agents; Drug Interactions; Humans; Immunologic Factors; Neoplasms; Xanthenes; Xanthones | 2002 |
Potential of DMXAA combination therapy for solid tumors.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Therapy; Genetic Therapy; Humans; Neoplasms; Neovascularization, Pathologic; Xanthenes; Xanthones | 2002 |
Antivascular therapy of cancer: DMXAA.
Topics: Antineoplastic Agents; Drug Design; Drugs, Investigational; Endothelium, Vascular; Humans; Microcirculation; Neoplasms; NF-kappa B; Xanthenes; Xanthones | 2003 |
Vascular targeting agents as cancer therapeutics.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Cell Division; Clinical Trials as Topic; Diphosphates; Genetic Therapy; Humans; Hypoxia; Immunotoxins; Ligands; Models, Biological; Necrosis; Neoplasms; Organophosphorus Compounds; Peptides; Radioimmunotherapy; Stilbenes; Time Factors; Up-Regulation; Xanthones | 2004 |
Clostridia in cancer therapy.
Topics: Animals; Antineoplastic Agents; Aziridines; Carcinoma; Clostridium; Cytosine Deaminase; Drug Delivery Systems; Humans; Mice; Neoplasms; Nitroreductases; Prodrugs; Spores, Bacterial; Xanthones | 2003 |
Novel vascular targeting/disrupting agents: combretastatin A4 phosphate and related compounds.
Topics: Antineoplastic Agents, Phytogenic; Clinical Trials, Phase I as Topic; Endothelium, Vascular; Humans; Neoplasms; Organophosphorus Compounds; Stilbenes; Xanthones | 2005 |
Disrupting tumour blood vessels.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Bibenzyls; Capillary Permeability; Clinical Trials as Topic; Endothelial Cells; Humans; Neoplasms; Neovascularization, Pathologic; Stilbenes; Xanthones | 2005 |
Current development status of small-molecule vascular disrupting agents.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Clinical Trials as Topic; Combined Modality Therapy; Disease Models, Animal; Drug Therapy, Combination; Humans; Neoplasms; Neovascularization, Pathologic; Regional Blood Flow; Stilbenes; Tubulin Modulators; Xanthones | 2006 |
Vascular disrupting agents in clinical development.
Topics: Animals; Antineoplastic Agents; Blood Vessels; Humans; Neoplasms; Neovascularization, Pathologic; Oligopeptides; Organophosphorus Compounds; Regional Blood Flow; Stilbenes; Tubulin Modulators; Xanthones | 2007 |
Small-molecule cytokine inducers causing tumor necrosis.
Topics: 5-Hydroxytryptophan; Animals; Antineoplastic Agents; Capillary Permeability; Cytokines; Endothelium, Vascular; Flavonoids; Humans; Interferon-alpha; Mice; Microcirculation; Necrosis; Neoplasms; NF-kappa B; Nitric Oxide; Tumor Necrosis Factor-alpha; Xanthenes; Xanthones | 2001 |
7 trial(s) available for vadimezan and Neoplasms
| Article | Year |
|---|---|
Transient retinal effects of 5,6-dimethylxanthenone-4-acetic acid (DMXAA, ASA404), an antitumor vascular-disrupting agent in phase I clinical trials.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Angiogenesis Inhibitors; Antineoplastic Agents; Color Perception Tests; Dose-Response Relationship, Drug; Electroretinography; Evoked Potentials, Visual; Humans; Infusions, Intravenous; Neoplasms; Phosphodiesterase Inhibitors; Retina; Retinal Diseases; Vision Disorders; Visual Acuity; Xanthones | 2009 |
The safety and tolerability of intravenous ASA404 when administered in combination with docetaxel (60 or 75 mg/m²) in Japanese patients with advanced or recurrent solid tumors.
Topics: Aged; Alopecia; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Appetite; Asian People; Constipation; Docetaxel; Drug Administration Schedule; Fatigue; Female; Fever; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Neutropenia; Severity of Illness Index; Taxoids; Treatment Outcome; Xanthones | 2011 |
Mass balance, excretion and metabolism of [¹⁴C] ASA404 in cancer patients in a phase I trial.
Topics: Aged; Antineoplastic Agents; Carbon Radioisotopes; Chromatography, High Pressure Liquid; Female; Humans; Infusions, Intravenous; Male; Mass Spectrometry; Middle Aged; Neoplasms; Protein Binding; Time Factors; Xanthones | 2012 |
Effects of 5,6-dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Contrast Media; Female; Humans; Image Enhancement; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Male; Microcirculation; Middle Aged; Muscle, Skeletal; Neoplasms; Reproducibility of Results; Xanthenes; Xanthones | 2002 |
Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Cardiovascular System; Female; Humans; Male; Middle Aged; Neoplasms; Nervous System; Treatment Outcome; Xanthenes; Xanthones | 2003 |
5,6-Dimethylxanthenone-4-acetic acid in the treatment of refractory tumors: a phase I safety study of a vascular disrupting agent.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Blood Pressure; Cross-Over Studies; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Electrocardiography; Female; Headache; Humans; Infusions, Intravenous; Long QT Syndrome; Male; Middle Aged; Nausea; Neoplasms; Treatment Outcome; Tremor; Xanthones | 2006 |
Population pharmacokinetic-pharmacodynamic model of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid in cancer patients.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Blood Vessels; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Hydroxyindoleacetic Acid; Male; Middle Aged; Neoplasms; Nonlinear Dynamics; Xanthones | 2008 |
24 other study(ies) available for vadimezan and Neoplasms
| Article | Year |
|---|---|
Binding-pocket and lid-region substitutions render human STING sensitive to the species-specific drug DMXAA.
Topics: Amino Acid Sequence; Animals; Antineoplastic Agents; Binding Sites; Chemokines; Crystallography, X-Ray; HEK293 Cells; Humans; Interferon Type I; Membrane Proteins; Mice; Molecular Dynamics Simulation; Molecular Sequence Data; Mutagenesis, Site-Directed; Neoplasms; Protein Structure, Tertiary; Recombinant Fusion Proteins; Sequence Alignment; Xanthones | 2014 |
Discovery of Non-Nucleotide Small-Molecule STING Agonists
Topics: Animals; Crystallography, X-Ray; Cyclic AMP; Cyclic GMP; Female; Humans; Immunity, Innate; Immunotherapy; Membrane Proteins; Mice; Mice, Inbred BALB C; Models, Molecular; Neoplasms; Signal Transduction; Small Molecule Libraries | 2022 |
Discovery of novel Thieno[2,3-d]imidazole derivatives as agonists of human STING for antitumor immunotherapy using systemic administration.
Topics: 14-alpha Demethylase Inhibitors; Humans; Imidazoles; Immunity, Innate; Immunotherapy; Membrane Proteins; Neoplasms | 2022 |
Structure-Activity relationship study of benzothiophene oxobutanoic acid analogues leading to novel stimulator of interferon gene (STING) agonists.
Topics: Animals; Humans; Immunotherapy; Interferons; Membrane Proteins; Mice; Neoplasms; Structure-Activity Relationship; Thiophenes; THP-1 Cells | 2022 |
Disrupting tumour vasculature and recruitment of aPDL1-loaded platelets control tumour metastasis.
Topics: Animals; Antineoplastic Agents; B7-H1 Antigen; Blood Platelets; Cell Line, Tumor; Female; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Neoplasm Metastasis; Neoplasms; Platelet Activation; Platelet Transfusion; Xanthones | 2021 |
Ultrasmall Hyperbranched Semiconducting Polymer Nanoparticles with Different Radioisotopes Labeling for Cancer Theranostics.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Injections, Intravenous; Iodine Radioisotopes; Isotope Labeling; Mice; Molecular Structure; Nanoparticles; Neoplasms; Particle Size; Polymers; Semiconductors; Surface Properties; Theranostic Nanomedicine; Tissue Distribution; Tomography, Emission-Computed, Single-Photon; Xanthones | 2018 |
Mouse, but not human STING, binds and signals in response to the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid.
Topics: Animals; Antineoplastic Agents; Cell Line; HEK293 Cells; Humans; Interferon Regulatory Factor-3; Interferon-beta; Leukocytes, Mononuclear; Macrophages; Membrane Proteins; Mice; Neoplasms; NF-kappa B; Protein Serine-Threonine Kinases; Signal Transduction; Xanthones | 2013 |
STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors.
Topics: Adaptive Immunity; Adaptor Proteins, Vesicular Transport; Animals; Antineoplastic Agents; Cells, Cultured; Cross-Priming; Dendritic Cells; DNA; Immunity, Innate; Interferon-beta; Membrane Proteins; Mice; Mice, Inbred C57BL; Mice, Knockout; Myeloid Differentiation Factor 88; Neoplasms; Nucleotides, Cyclic; Nucleotidyltransferases; Radiation, Ionizing; Receptor, Interferon alpha-beta; RNA Interference; RNA, Small Interfering; Signal Transduction; Xanthones | 2014 |
Microenvironment-Mediated Modeling of Tumor Response to Vascular-Targeting Drugs.
Topics: Angiogenesis Inhibitors; Bevacizumab; Bibenzyls; Computer Simulation; Cytotoxins; Drug Combinations; Drug Dosage Calculations; Endothelial Cells; Everolimus; Humans; Models, Statistical; Neoplasms; Neovascularization, Pathologic; Tumor Microenvironment; Xanthones | 2016 |
The development of the tumor vascular-disrupting agent ASA404 (vadimezan, DMXAA): current status and future opportunities.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Drug Evaluation, Preclinical; Humans; Neoplasms; Neovascularization, Pathologic; Randomized Controlled Trials as Topic; Xanthones | 2010 |
Novel agents target existing tumor vasculature.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Drug Delivery Systems; Humans; Neoplasms; Neovascularization, Pathologic; Xanthones | 2010 |
Clinical development of vascular disrupting agents: what lessons can we learn from ASA404?
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials, Phase III as Topic; Data Interpretation, Statistical; Drug Synergism; Female; Humans; Lung Neoplasms; Molecular Targeted Therapy; Neoplasms; Randomized Controlled Trials as Topic; Research Design; Survival Analysis; Treatment Failure; Vascular Endothelial Growth Factor A; Xanthones | 2011 |
Cardiovascular toxicity profiles of vascular-disrupting agents.
Topics: Angiogenesis Inhibitors; Bibenzyls; Cardiovascular System; Clinical Trials as Topic; Humans; Neoplasms; Neovascularization, Pathologic; Organophosphorus Compounds; Quinazolines; Serine; Xanthones | 2011 |
Influence of the vascular damaging agents DMXAA and ZD6126 on hypericin distribution and accumulation in RIF-1 tumors.
Topics: Animals; Anthracenes; Antineoplastic Agents; Cell Line, Tumor; Mice; Mice, Inbred C3H; Necrosis; Neoplasms; Neovascularization, Pathologic; Organophosphorus Compounds; Perylene; Telomere-Binding Proteins; Xanthones | 2011 |
Combination of vascular targeting agents with thermal or radiation therapy.
Topics: Adjuvants, Immunologic; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Dose-Response Relationship, Radiation; Flavonoids; Hyperthermia, Induced; Mice; Mice, Inbred C3H; Neoplasm Transplantation; Neoplasms; Neovascularization, Pathologic; Stilbenes; Temperature; Time Factors; Tumor Cells, Cultured; X-Rays; Xanthenes; Xanthones | 2002 |
Requirements for ICAM-1 immunogene therapy of lymphoma.
Topics: Animals; CD8-Positive T-Lymphocytes; Cell Adhesion; COS Cells; Cytoplasm; DNA, Complementary; Flow Cytometry; Gene Transfer Techniques; Genetic Therapy; Genetic Vectors; Humans; Immunotherapy; Intercellular Adhesion Molecule-1; Killer Cells, Natural; Leukocytes; Lymphoma; Mice; Mutation; Neoplasms; Plasmids; Protein Structure, Tertiary; Signal Transduction; Time Factors; Transfection; Transgenes; Xanthones | 2003 |
Vascular disrupting agents.
Topics: Angiogenesis Inhibitors; Animals; Flavonoids; Ligands; Neoplasms; Tubulin; Xanthones | 2006 |
Assessment of tumor response to the vascular disrupting agents 5,6-dimethylxanthenone-4-acetic acid or combretastatin-A4-phosphate by intrinsic susceptibility magnetic resonance imaging.
Topics: Angiogenesis Inhibitors; Animals; Biomarkers, Tumor; Female; Hemoglobins; Magnetic Resonance Imaging; Neoplasms; Neovascularization, Pathologic; Rats; Rats, Inbred WF; Stilbenes; Xanthones | 2007 |
Hypoxia-activated prodrugs as antitumour agents: strategies for maximizing tumour cell killing.
Topics: Aniline Mustard; Animals; Antineoplastic Agents; Cell Hypoxia; Mice; Neoplasms; Nitrogen Mustard Compounds; Prodrugs; Xanthenes; Xanthones | 1995 |
Comparative effects of combretastatin A-4 disodium phosphate and 5,6-dimethylxanthenone-4-acetic acid on blood perfusion in a murine tumour and normal tissues.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Blood; Digestive System; Dose-Response Relationship, Drug; Female; Kidney; Liver; Lung; Mice; Mice, Inbred C3H; Muscles; Neoplasm Transplantation; Neoplasms; Perfusion; Skin; Spleen; Stilbenes; Time Factors; Tissue Distribution; Tumor Cells, Cultured; Urinary Bladder; Xanthenes; Xanthones | 2001 |
Reversible binding of the novel anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid to plasma proteins and its distribution into blood cells in various species.
Topics: Animals; Antineoplastic Agents; Blood Cells; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Humans; Male; Neoplasms; Protein Binding; Rabbits; Rats; Rats, Wistar; Xanthenes; Xanthones | 2001 |
Measurement of plasma 5-hydroxyindoleacetic acid as a possible clinical surrogate marker for the action of antivascular agents.
Topics: Angiogenesis Inhibitors; Biomarkers; Calibration; Chromatography, High Pressure Liquid; Clinical Trials, Phase I as Topic; Electrochemistry; Humans; Hydroxyindoleacetic Acid; Neoplasms; Quality Control; Reference Standards; Regional Blood Flow; Reproducibility of Results; Solutions; Xanthenes; Xanthones | 2001 |
Species differences in the metabolism of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid in vitro: implications for prediction of metabolic interactions in vivo.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Humans; In Vitro Techniques; Kidney; Liver; Mice; Microsomes; Microsomes, Liver; Neoplasms; Rabbits; Rats; Species Specificity; Xanthenes; Xanthones | 2002 |
Reproducibility of dynamic contrast-enhanced MRI in human muscle and tumours: comparison of quantitative and semi-quantitative analysis.
Topics: Antineoplastic Agents; Bibenzyls; Contrast Media; Humans; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Muscle, Skeletal; Neoplasms; Reproducibility of Results; Stilbenes; Xanthenes; Xanthones | 2002 |